Trial Profile

Neoadjuvant Teripalimab Plus Chemotherapy in Local Advanced Esophageal Squamous Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 03 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cisplatin (Primary) ; Paclitaxel (Primary) ; Toripalimab (Primary)
Indications Oesophageal cancer; Squamous cell cancer; Thoracic neoplasms
Focus Therapeutic Use

Most Recent Events

20 Jul 2021 New trial record
08 Jun 2021 Primary endpoint (Pathological complete response rate) has not been met, as per results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
08 Jun 2021 Results assessing safety and rate of pCR of chemotherapy plus anti-PD-1 therapy and the influence of sequence of chemotherapy and anti-PD-1 therapy on pCR in patients with locally advanced esophageal squamous cell cancer, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com